Cynthia C. Morton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cynthia C. Morton has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Azra H. Ligon
Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
3 shared publicationsCharles Lee
3 shared publicationsNahid G. Robertson
Brigham and Women's Hospital, Boston, MA 02115
3 shared publicationsStanislawa Weremowicz
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
3 shared publicationsBarbara L. Resendes
Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA 02115, USA
2 shared publicationsBradley J. Quade
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
2 shared publications
Latest Publications
- 1 September 2002
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 137 (2) , 133-137
PCOLCE deletion and expression analyses in uterine leiomyomata
- 1 September 2002
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 137 (2) , 133-137
PCOLCE deletion and expression analyses in uterine leiomyomata
- Open Access
- 3 October 2001
- Published by Springer Nature in Journal of the Association for Research in Otolaryngology
- Vol. 3 (1) , 45-53
Gene discovery in the auditory system: characterization of additional cochlear-expressed sequences.
- 3 October 2001
- Published by Springer Nature in Journal of the Association for Research in Otolaryngology
- Vol. 3 (1) , 45-53
Open AccessGene discovery in the auditory system: characterization of additional cochlear-expressed sequences.
- Open Access
- 1 October 2001
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 10 (22) , 2493-2500
Inner ear localization of mRNA and protein products of COCH, mutated in the sensorineural deafness and vestibular disorder, DFNA9
Missense mutations in the COCH gene, which is expressed preferentially at high levels in the inner ear, cause the autosomal dominant sensorineural deafness and vestibular disorder, DFNA9 (OMIM 601369). By in situ hybridization of mouse and human inner ear sections, we find high-level expression of COCH mRNA in the fibrocytes of the spiral limbus and of the spiral ligament in the cochlea, and in the fibrocytes of the connective tissue stroma underlying the sensory epithelium of the crista ampullaris of the semicircular canals. A polyclonal antibody against the human COCH protein product, cochlin, was raised against the N-terminal 135 amino acid residues of cochlin, corresponding to the Limulus factor C-homology (cochFCH) domain; this domain harbors all five known point mutations in DFNA9. On western blots of human fetal cochlear extracts, anti-cochlin reacts with a cochlin band of the predicted full-length size as well as a smaller isoform. Immunohistochemistry performed with anti-cochlin shows staining predominantly in the regions of the fibrocytes of the spiral limbus and of the spiral ligament in mouse and in human fetal and adult tissue sections. These sites correspond to those areas that express COCH mRNA as determined by in situ hybridization, and to the regions of the inner ear which show histological abnormalities in DFNA9. The fibrocytes expressing mRNA and protein products of COCH are the very cell types which are either absent or markedly reduced and replaced by eosinophilic acellular material in temporal bone sections of individuals affected with DFNA9.
- 1 October 2001
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 10 (22) , 2493-2500
Open AccessInner ear localization of mRNA and protein products of COCH, mutated in the sensorineural deafness and vestibular disorder, DFNA9
Missense mutations in the COCH gene, which is expressed preferentially at high levels in the inner ear, cause the autosomal dominant sensorineural deafness and vestibular disorder, DFNA9 (OMIM 601369). By in situ hybridization of mouse and human inner ear sections, we find high-level expression of COCH mRNA in the fibrocytes of the spiral limbus and of the spiral ligament in the cochlea, and in the fibrocytes of the connective tissue stroma underlying the sensory epithelium of the crista ampullaris of the semicircular canals. A polyclonal antibody against the human COCH protein product, cochlin, was raised against the N-terminal 135 amino acid residues of cochlin, corresponding to the Limulus factor C-homology (cochFCH) domain; this domain harbors all five known point mutations in DFNA9. On western blots of human fetal cochlear extracts, anti-cochlin reacts with a cochlin band of the predicted full-length size as well as a smaller isoform. Immunohistochemistry performed with anti-cochlin shows staining predominantly in the regions of the fibrocytes of the spiral limbus and of the spiral ligament in mouse and in human fetal and adult tissue sections. These sites correspond to those areas that express COCH mRNA as determined by in situ hybridization, and to the regions of the inner ear which show histological abnormalities in DFNA9. The fibrocytes expressing mRNA and protein products of COCH are the very cell types which are either absent or markedly reduced and replaced by eosinophilic acellular material in temporal bone sections of individuals affected with DFNA9.
- 1 May 2001
- Published by Wiley in American Journal of Medical Genetics
- Vol. 100 (3) , 246-250
Prenatal diagnosis and molecular cytogenetics in a case of partial trisomy 14 and monosomy 21
We report an unbalanced translocation involving chromosomes 14 and 21 which presented as fetal ventriculomegaly at 33 weeks gestation. Second trimester ultrasound had indicated normal fetal anatomy, including normal intracranial structures. Parental karyotypes showed a paternal balanced translocation: 46,XY,t(14;21)(q12;q21). The unbalanced translocation in the fetus resulted in trisomy for 14pter→q12 and monosomy for 21pter→q21. Postnatal examination showed that the male infant had a cleft palate, but no cleft lip, and mild dysmorphic features. Postnatal MRI revealed bilateral and symmetric dilatation of the occipital horns, atria, and temporal horns of the lateral ventricles. Molecular cytogenetic techniques were used to delineate further the breakpoint on chromosome 14 to a site distal of the D14S1071 locus and the breakpoint on chromosome 21 to a region between D21S1918 and D21S1902. More precise definitions of chromosomal breakpoints in such clinical cases should provide more accurate prognosis for individuals with unbalanced karyotypes and assist in the identification of putative developmentally important genes.
- 1 May 2001
- Published by Wiley in American Journal of Medical Genetics
- Vol. 100 (3) , 246-250
Prenatal diagnosis and molecular cytogenetics in a case of partial trisomy 14 and monosomy 21
We report an unbalanced translocation involving chromosomes 14 and 21 which presented as fetal ventriculomegaly at 33 weeks gestation. Second trimester ultrasound had indicated normal fetal anatomy, including normal intracranial structures. Parental karyotypes showed a paternal balanced translocation: 46,XY,t(14;21)(q12;q21). The unbalanced translocation in the fetus resulted in trisomy for 14pter→q12 and monosomy for 21pter→q21. Postnatal examination showed that the male infant had a cleft palate, but no cleft lip, and mild dysmorphic features. Postnatal MRI revealed bilateral and symmetric dilatation of the occipital horns, atria, and temporal horns of the lateral ventricles. Molecular cytogenetic techniques were used to delineate further the breakpoint on chromosome 14 to a site distal of the D14S1071 locus and the breakpoint on chromosome 21 to a region between D21S1918 and D21S1902. More precise definitions of chromosomal breakpoints in such clinical cases should provide more accurate prognosis for individuals with unbalanced karyotypes and assist in the identification of putative developmentally important genes.
- 1 April 2001
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 68 (4) , 1043-1047
Limitations of Chromosome Classification by Multicolor Karyotyping
- 1 April 2001
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 68 (4) , 1043-1047
Limitations of Chromosome Classification by Multicolor Karyotyping
- Open Access
- 1 January 2001
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 7 (1) , 8-14
Leiomyomata: heritability and cytogenetic studies
Leiomyomata represent the most common gynaecological tumour in women of reproductive age, and are the primary indication for hysterectomy in the USA. Cytogenetic and genetic studies have, in recent years, advanced our understanding of the aetiology of these tumours. Cytogenetic aberrations involving chromosomes 6, 7, 12 and 14 constitute the major chromosomal abnormalities seen in leiomyomata, and suggest the possibility that disruption or dysregulation of the genes HMGIC and HMGIY may contribute to the development of these tumours. Based on the finding of a variety of chromosomal aberrations detected in fibroids, other genes with fundamental roles in the pathobiology of uterine leiomyomata await identification. Furthermore, the incidence of fibroids has been shown to be greater in African-American women than in Caucasian women. The existence of a heritability component of uterine leiomyomata has been further implicated by twin-pair studies and the existence of familial forms of leiomyomata, both of which suggest an inherited diathesis for leiomyomata formation. This paper will review the cytogenetic aberrations and gene expression, with respect to their contributions to the pathogenesis of leiomyomata, and also summarize the current understanding of heritability of these tumours.
- 1 January 2001
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 7 (1) , 8-14
Open AccessLeiomyomata: heritability and cytogenetic studies
Leiomyomata represent the most common gynaecological tumour in women of reproductive age, and are the primary indication for hysterectomy in the USA. Cytogenetic and genetic studies have, in recent years, advanced our understanding of the aetiology of these tumours. Cytogenetic aberrations involving chromosomes 6, 7, 12 and 14 constitute the major chromosomal abnormalities seen in leiomyomata, and suggest the possibility that disruption or dysregulation of the genes HMGIC and HMGIY may contribute to the development of these tumours. Based on the finding of a variety of chromosomal aberrations detected in fibroids, other genes with fundamental roles in the pathobiology of uterine leiomyomata await identification. Furthermore, the incidence of fibroids has been shown to be greater in African-American women than in Caucasian women. The existence of a heritability component of uterine leiomyomata has been further implicated by twin-pair studies and the existence of familial forms of leiomyomata, both of which suggest an inherited diathesis for leiomyomata formation. This paper will review the cytogenetic aberrations and gene expression, with respect to their contributions to the pathogenesis of leiomyomata, and also summarize the current understanding of heritability of these tumours.
- 1 October 2000
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 108 (s5) , 775-778
Genetic Approaches to the Study of Uterine Leiomyomata
The use of a variety of genetic methods to dissect underlying molecular events in tumors continues to be a highly successful approach. Cytogenetic evaluations of uterine leiomyomata have revealed consistent rearrangements that have provided biological landmarks for positional cloning experiments. Genetic linkage analysis makes possible the identification of genes that might predispose women to develop myomas. New gene expression chip methods to study globally the transcripts present in uterine leiomyomata promise insight into molecular pathways in tumor biology.
- 1 October 2000
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 108 (s5) , 775-778
Genetic Approaches to the Study of Uterine Leiomyomata
The use of a variety of genetic methods to dissect underlying molecular events in tumors continues to be a highly successful approach. Cytogenetic evaluations of uterine leiomyomata have revealed consistent rearrangements that have provided biological landmarks for positional cloning experiments. Genetic linkage analysis makes possible the identification of genes that might predispose women to develop myomas. New gene expression chip methods to study globally the transcripts present in uterine leiomyomata promise insight into molecular pathways in tumor biology.
- 1 June 2000
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 28 (3) , 235-245
Genetics of uterine leiomyomata
- 1 June 2000
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 28 (3) , 235-245
Genetics of uterine leiomyomata
- 1 February 2000
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 27 (2) , 209-215
Dysregulation of HMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14
- 1 February 2000
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 27 (2) , 209-215
Dysregulation of HMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14
- 7 July 1999
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 25 (4) , 316-322
HMGIC expression in human adult and fetal tissues and in uterine leiomyomata
- 7 July 1999
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 25 (4) , 316-322
HMGIC expression in human adult and fetal tissues and in uterine leiomyomata